Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FCER2 | P06734 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 2/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 2/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | OXTR | P30559 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3067947 | 0.92 | FCER2 (0.37) | FCER2MMP1ACEMMEOXTR | |
| SCHEMBL2969632 | 0.90 | FCER2 (0.46) | FCER2MMP1ACEMME | |
| SCHEMBL2979121 | 0.88 | FCER2 (0.40) | FCER2MMP1ACEMMEERAP2 | |
| SCHEMBL2978574 | 0.85 | CD274 (0.34) | — | |
| SCHEMBL2978569 | 0.84 | ALDH1A1 (0.36) | ACEMME | |
| SCHEMBL2973536 | 0.82 | FCER2 (0.38) | FCER2MMP1ACEMMEOXTR | |
| SCHEMBL2977231 | 0.82 | FCER2 (0.45) | FCER2MMP1ACEMME | |
| SCHEMBL2977806 | 0.81 | FEN1 (0.33) | ALOX5APFEN1 | |
| SCHEMBL3054815 | 0.80 | MME (0.40) | FCER2ACEMME | |
| SCHEMBL2976589 | 0.80 | FCER2 (0.40) | FCER2MMP1ACEMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735625-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2014-05-27 | — | — | US | disclosed |
| US-20140046075-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8394846-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20120129900-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20100267788-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7777077-B2 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | THERAVANCE, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080188533-A1 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267788-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | FCER2 1264/4885MMP1 1347/4885ACE 7/4885 |
| US-20140046075-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | FCER2 1264/4885MMP1 1347/4885ACE 7/4885 |
| US-20080188533-A1 | 2-Mercaptomethyl-4-methylpentanoic Acid (2-Butyryl-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]aminoethyl)amide | MME, AGTR1, AGTR2 | FCER2 1056/4885MMP1 1816/4885ACE 10/4885 |
| US-20120129900-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | FCER2 1264/4885MMP1 1347/4885ACE 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.